60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP
60 Degrees Pharmaceuticals — H.C. Wainwright Presentation September 2026
19 slides from 60 Degrees Pharmaceuticals's conference presentation, Sep 8, 2026
Slide 1: H.C. Wainwright Presentation: Targeted therapies for vector-borne disease
H.C. Wainwright Presentation 60 Degrees Pharmaceuticals, Inc. September 2026 Targeted therapies for vector-borne disease Investment focus A marketed antimalarial platform creates a path to potential indication expansion in babesiosis Commercial base ARAKODA® malaria prophylaxis Clinical vector Babes
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and does not purport to be all- inclusive or to contain all of the information a
Slide 3: Investment Thesis
60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 3 Investment Thesis A marketed antimalarial platform creates a staged path to potential indication expansion in babesiosis. Core thesis Label expansion of ARAKODA® / tafenoquine from malaria prevention into high-need tick-
Slide 4: Financial Snapshot: Q2 2026 results + July financing
Financial Snapshot Q2 2026 results + July financing / Knight conversion Q2 10-Q filed Aug. 14, 2026 COMMON OUTSTANDING/MARKET CAP ~3.51M/ ~4M Pro forma at Jul. 31: 2.659M base + 658.6k Knight conversion + 191.6k common issued in financing. Excludes pre-funded warrants. PREFERRED OUTSTANDING 68,080 S
Slide 5: Ticks Transmit a Widening Set of Serious Diseases in the U.S.
Ticks Transmit a Widening Set of Serious Diseases in the U.S. Record tick-bite emergency room visits in 2026 underscore the rising need for targeted therapies. ER visits for tick bites RECORD LEVELS THIS YEAR (113,000+) More bites → more clinical encounters One bite can transmit multiple pathogens E
Slide 6: Critical Unmet Need in Selected Tick-Borne and Tick-Associated Diseases
©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 66 Critical Unmet Need in Selected Tick-Borne and Tick-Associated Diseases High burden, limited approved options, and a clear rationale for small-molecule repositioning Babesiosis Parasitic red-blood-cell infection B ≥25k claim
Slide 7: Portfolio: Phases and Development Stages
Portfolio August 2026 PHASES AND DEVELOPMENT STAGES PRODUCT NON-CLINICAL IND ENABLING PHASE 1 PHASE IIA Phase IIB/III REGULATORY REVIEW COMMERCIALLY AVAILABLE COMMERCIALLY SUSTAINABLE ARAKODA® (US) ZAMVIO (tafenoquine): TICK-BORNE DISEASE – VETERINARY INDICATIONS Preparing dossier for FDA meeting Ta
Slide 8: Signs and symptoms of babesiosis
8 Source: CDC signs/symptoms of babesiosis. Chronic / severe fatigue Persistent fatigue may drive prolonged recovery 8
Slide 9: Babesiosis Treatment Gap
60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 9 Babesiosis Treatment Gap Current regimens leave a high-need refractory segment with limited evidence and no FDA-approved options. STANDARD OF CARE TODAY First-line treatment Atovaquone + azithromycin ↓ Treatment-refractor
Slide 10: Babesiosis: An Orphan Disease With Three Distinct Unmet Need Segments
60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 10 Babesiosis: An Orphan Disease With Three Distinct Unmet Need Segments Hospitalized acute disease, refractory immunosuppressed disease, and chronic/persistent symptoms create multiple treatment opportunities. Severe Disea
Slide 11: ARAKODA: FDA-approved for malaria prophylaxis
11 adult age group indicated 11 11 11 2018 US FDA approval 2019 commercially available Indicated for prophylaxis of malaria in adults 8 studies >1,100 patients 52 weeks AE rate comparable to placebo; G6PD screening required.
Slide 12: Tafenoquine & Babesiosis: Non-Clinical Proof of Concept
Tafenoquine & Babesiosis: Non-Clinical Proof of Concept Blood-smear phenotype plus SCID-mouse combination data support repositioning into Babesia. BLOOD-SMEAR PHENOTYPE (LIU ET AL.) Giemsa-stained blood smears from B. rodhaini-infected mice; 24 hours post single-dose tafenoquine vs. vehicle; H₂O₂ in
Slide 13: Treatment-Refractory Babesiosis: Human Case-Series Signal
13 13 13 Treatment-Refractory Babesiosis: Human Case-Series Signal Tafenoquine combinations cured 4 of 4 immunosuppressed patients when administered concurrently for >8 weeks. 13 >8 wks concurrent tafenoquine + atovaquone + antibiotic combinations 1 Human signal Cure observed in difficult-to-treat i
Slide 14: Babesiosis Could Triple the ARAKODA Asset Opportunity
Babesiosis Could Triple the ARAKODA® Asset Opportunity Patient exclusivity creates two ways to expand the same marketed antimalarial platform: treated patients and treatment-course value. PATIENT CASELOAD OPPORTUNITY VALUE OPPORTUNITY AT CURRENT WAC Maximum cumulative addressable market (2026Q3–2035
Slide 15: Tafenoquine + SOC vs placebo + SOC study design
15 Tafenoquine + SOC vs placebo + SOC TQ dose: 200 mg × 4, then 200 mg weekly for 4 weeks Primary: TTSCR* 200 mg weekly following the load through Day 90 *TTSCR = time to sustained clinical resolution; TTMC = time to molecular cure. 15 15 15 NAT test used to define cure
Slide 16: Objective: Align with FDA on NAT as a relapse surrogate
16 Objective: Align with FDA on NAT as a relapse surrogate and a confirmatory-study path that can support indication expansion. 16 16 16
Slide 17: FDA precedent: Wellcovorin/leucovorin supplemental approval
17 Sources: FDA press announcement and supplemental approval materials for Wellcovorin/leucovorin calcium (Mar. 2026). 17 17 17
Slide 18: Derisked Regulatory Pathway: Regular sNDA
18 Hospital study efficacy plus expanded access cure data could support lower risk regulatory approval pathway 18 18 18 Derisked Regulatory Pathway: Regular sNDA
Slide 19: Potential PDUFA date and other anticipated milestones
19 Potential PDUFA date with priority review 19 OTHER ANTICIPATED MILESTONES New product collaborations • market updates • other product research updates Potential PDUFA date with priority review 19 OTHER ANTICIPATED MILESTONES New product collaborations • market updates • other product research upd
60 Degrees Pharmaceuticals — H.C. Wainwright Presentation September 2026 on 6ix